The most recent clinical trial result is the chimeric antigen receptor (CAR) T cell therapy Kymriah? It has been shown that (tisagenlecleucel, formerly known as CTL019) can lead to long-term remission in patients with recurrent diffuse large B-cell lymphoma (DLBCL).
The latest results of this research were presented at the 60th Annual Meeting of the American Society of Hematology (ASH) and Expo recently held in San Diego. Dr. Stephen J. Schuster, director of the Lymphoma Program at the Abramson Cancer Center at the University of Pennsylvania, is the principal investigator of the JULIET trial, and another early discontinuation data set is also published in the New England Journal of Medicine.
JULIET has 27 sites in 10 countries/regions: North America, Europe, Australia and Asia. According to the data provided by ASH, 115 patients with DLBCL received CART treatment. The total remission rate of the evaluable patients was 54%, of which 40% achieved complete remission. The median duration of these reactions did not reach the median follow-up time of 19 months. One of the researchers, Shu said: "These findings are consistent with the results of a single-point study at the University of Pennsylvania, which means that most patients in remission are in remission." Dr. Star said.
"For these patients, CART therapy is a potentially life-saving alternative, even after other therapies, including transplants, have failed, they can now help them achieve lasting relief. I have a therapy that can be done," Shu Steward said.
treatment will change the patient's own immune T cells. Immune T cells can be collected and reprogrammed to find and destroy cancer cells in the patient. After these CAR-expressing T cells are injected into the patient, they proliferate and attack, targeting cells that express CD19 protein. Tests have shown that for each prosthetic patient, the hunter cell population can grow into more than 10,000 new cells with a high remission rate. They can also survive in the body for several years.